» Articles » PMID: 37729916

Ligand Flexibility and Binding Pocket Malleability Cooperate to Allow Selective PXR Activation by Analogs of a Promiscuous Nuclear Receptor Ligand

Overview
Journal Structure
Publisher Cell Press
Date 2023 Sep 20
PMID 37729916
Authors
Affiliations
Soon will be listed here.
Abstract

The human nuclear receptor (NR) family of transcription factors contains 48 proteins that bind lipophilic molecules. Approved NR therapies have had immense success treating various diseases, but lack of selectivity has hindered efforts to therapeutically target the majority of NRs due to unpredictable off-target effects. The synthetic ligand T0901317 was originally discovered as a potent agonist of liver X receptors (LXRα/β) but subsequently found to target additional NRs, with activation of pregnane X receptor (PXR) being as potent as that of LXRs. We previously showed that directed rigidity reduces PXR binding by T0901317 derivatives through unfavorable protein remodeling. Here, we use a similar approach to achieve selectivity for PXR over other T0901317-targeted NRs. One molecule, SJPYT-318, accomplishes selectivity by favorably utilizing PXR's flexible binding pocket and surprisingly binding in a new mode distinct from the parental T0901317. Our work provides a structure-guided framework to achieve NR selectivity from promiscuous compounds.

Citing Articles

A two-in-one expression construct for biophysical and structural studies of the human pregnane X receptor ligand-binding domain, a pharmaceutical and environmental target.

Carivenc C, Laconde G, Blanc P, Amblard M, Bourguet W, Delfosse V Acta Crystallogr F Struct Biol Commun. 2025; 81(Pt 3):85-94.

PMID: 39923198 PMC: 11866411. DOI: 10.1107/S2053230X2500069X.


PROTAC-mediated activation, rather than degradation, of a nuclear receptor reveals complex ligand-receptor interaction network.

Huber A, Lin W, Poudel S, Miller D, Chen T Structure. 2024; 32(12):2352-2363.e8.

PMID: 39389062 PMC: 11647748. DOI: 10.1016/j.str.2024.09.016.


Costs of molecular adaptation to the chemical exposome: a focus on xenobiotic metabolism pathways.

Tomkiewicz C, Coumoul X, Nioche P, Barouki R, Blanc E Philos Trans R Soc Lond B Biol Sci. 2024; 379(1898):20220510.

PMID: 38310928 PMC: 10838638. DOI: 10.1098/rstb.2022.0510.


Regulation of PXR in drug metabolism: chemical and structural perspectives.

Gee R, Huber A, Chen T Expert Opin Drug Metab Toxicol. 2024; 20(1-2):9-23.

PMID: 38251638 PMC: 10939797. DOI: 10.1080/17425255.2024.2309212.


A bromodomain-independent mechanism of gene regulation by the BET inhibitor JQ1: direct activation of nuclear receptor PXR.

Huber A, Poudel S, Wu J, Miller D, Lin W, Yang L Nucleic Acids Res. 2023; 52(4):1661-1676.

PMID: 38084912 PMC: 10899790. DOI: 10.1093/nar/gkad1175.

References
1.
Sartor R . Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Aliment Pharmacol Ther. 2015; 43 Suppl 1:27-36. DOI: 10.1111/apt.13436. View

2.
Venkatesh M, Mukherjee S, Wang H, Li H, Sun K, Benechet A . Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity. 2014; 41(2):296-310. PMC: 4142105. DOI: 10.1016/j.immuni.2014.06.014. View

3.
Lazar M . Maturing of the nuclear receptor family. J Clin Invest. 2017; 127(4):1123-1125. PMC: 5373857. DOI: 10.1172/JCI92949. View

4.
Xue Y, Chao E, Zuercher W, Willson T, Collins J, Redinbo M . Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. Bioorg Med Chem. 2007; 15(5):2156-66. PMC: 1839856. DOI: 10.1016/j.bmc.2006.12.026. View

5.
Weikum E, Liu X, Ortlund E . The nuclear receptor superfamily: A structural perspective. Protein Sci. 2018; 27(11):1876-1892. PMC: 6201731. DOI: 10.1002/pro.3496. View